EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cost-Utility Analysis of TAVI Versus Surgery in Low-Risk Patients with Severe Aortic Stenosis in the UK

Nick Curzen, Pascal Candolfi iD, Philip MacCarthy, Clinton T Lloyd, Muhammad Aetesam-Ur-Rahman, Tom Bromilow, Valentina Sellitto, Daniel J Blackman

Applied Health Economics and Health Policy · 2026-03 · 24 (2) · 365-378

DOI: 10.1007/s40258-025-01012-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Applied Health Economics and Health Policy, online erschienen am 07.11.2025. Verfasst von Nick Curzen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Southampton, Southampton, UK. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Heart Valve Prosthesis Implantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Edwards Lifesciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: European guidelines recommend transcatheter aortic valve implantation (TAVI; class IA) for symptomatic severe aortic stenosis (sSAS) in patients aged ≥ 75 years, if a transfemoral approach is possible. Recent cost-utility analyses based on the PARTNER 3 trial have suggested that TAVI with the SAPIEN 3 device is cost effective versus surgical aortic valve replacement (SAVR) in patients at low risk of surgical mortality in several European countries. This cost-utility analysis compares TAVI with SAPIEN 3 versus SAVR in patients with sSAS at low risk of surgical mortality from the UK healthcare system perspective, using 5-year PARTNER 3 trial data. METHODS: A two-stage, Markov-based, cost-utility analysis was performed using published and validated methodology to estimate changes in both direct healthcare costs and health-related quality of life for TAVI with SAPIEN 3 versus SAVR in patients with sSAS at low surgical risk from the perspective of the UK healthcare system. The model used a lifetime horizon with a 3.5% yearly discounting factor. Uncertainty was addressed using deterministic and probabilistic sensitivity analyses. RESULTS: Transcatheter aortic valve implantation with SAPIEN 3 generated an incremental health benefit of 0.47 (90% credible interval 0.35-0.60) quality-adjusted life-years per patient compared with SAVR, at an increased cost of £7999 (£852-£15,035 90% credible interval) per patient over a lifetime horizon (incremental cost-effectiveness ratio: £16,979 per quality-adjusted life-year gained). Transcatheter aortic valve implantation has a 63-90% probability of cost effectiveness based on a £20,000-£30,000 willingness-to-pay threshold. Transcatheter aortic valve implantation remained cost effective across most deterministic sensitivity analyses, confirming the relative robustness of the results. CONCLUSIONS: Transcatheter aortic valve implantation with SAPIEN 3 has a 63-90% probability of being cost effective compared with SAVR for low-surgical-risk patients with sSAS. These findings may inform policy decision making in the management of this patient group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcatheter Aortic Valve ReplacementAortic Valve StenosisHeart Valve Prosthesis ImplantationHumansCost-Benefit AnalysisUnited KingdomAgedAged, 80 and overQuality-Adjusted Life YearsMarkov ChainsMaleFemaleQuality of Life

Autor:innen und Institutionen

  • Faculty of Medicine, University of Southampton, Southampton, UK.
  • Cardiothoracic Unit, University Hospital Southampton NHS Trust, Southampton, UK.
  • Edwards Lifesciences Sàrl, Route de l'Etraz 70, 1260, Nyon, Switzerland. pascal_candolfi@edwards.com.
  • King's College Hospital, London, UK.
  • University Hospitals Plymouth NHS Trust, Plymouth, UK.
  • Sheffield Teaching Hospitals NHS FT, Sheffield, UK.

ORCID-Profile: Pascal Candolfi

Förderung

  • Edwards Lifesciences

Zitieren

APA

Curzen, N., Candolfi, P., MacCarthy, P., Lloyd, C. T., Aetesam-Ur-Rahman, M., Bromilow, T., Sellitto, V., & Blackman, D. J. (2026). Cost-Utility Analysis of TAVI Versus Surgery in Low-Risk Patients with Severe Aortic Stenosis in the UK. Applied Health Economics and Health Policy, 24(2), 365-378. https://doi.org/10.1007/s40258-025-01012-4

Vancouver

Curzen N, Candolfi P, MacCarthy P, Lloyd CT, Aetesam-Ur-Rahman M, Bromilow T, et al. Cost-Utility Analysis of TAVI Versus Surgery in Low-Risk Patients with Severe Aortic Stenosis in the UK. Applied Health Economics and Health Policy. 2026;24(2):365-378. doi:10.1007/s40258-025-01012-4

BibTeX
@article{Curzen2026,
  author = {Curzen, Nick and Candolfi, Pascal and MacCarthy, Philip and Lloyd, Clinton T and Aetesam-Ur-Rahman, Muhammad and Bromilow, Tom and Sellitto, Valentina and Blackman, Daniel J},
  title = {Cost-Utility Analysis of TAVI Versus Surgery in Low-Risk Patients with Severe Aortic Stenosis in the UK},
  journal = {Applied Health Economics and Health Policy},
  year = {2026},
  volume = {24},
  number = {2},
  pages = {365--378},
  doi = {10.1007/s40258-025-01012-4}
}
Kostenlos starten →